한국어
English
日本語
中文(简体)
Stivarga 40 mg (Regorafenib)
41.49mg
Tablet · Prescription medication
Bayer Korea Co., Ltd.
Regorafenib is an antineoplastic agent that inhibits the growth of malignant tumors.
MFDS ingredient code M118337
Regorafenib is an antineoplastic agent that belongs to the class of multi-kinase inhibitors. This agent is used to inhibit tumor growth by disrupting the proliferation of cancer cells and angiogenesis.
Regorafenib blocks the activity of several proteins that promote blood vessel formation around the cancer cells. This reduces the blood supply necessary for tumors and inhibits the proliferation of cancer cells.
Approved uses differ by product. Check each product's information for its actual use.
Regorafenib has the characteristic of simultaneously inhibiting several types of protein kinases, resulting in a broader anticancer effect than single-target inhibitors. This makes it useful in the treatment of various malignant tumors.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.